| |
Article Title |
Author(s) |
Pages |
|
|
|
Letter from the editors
THE DREAM that antibodies could be produced that would make targeted radioimmunotherapy possible has been shared by many investigators during the past three decades. After numerous failures to achieve...
|
Leonard M. Freeman,
M.Donald Blaufox
|
1
|
|
|
|
Radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin): The role of the nuclear medicine physician
Abstract: Radioimmunotherapy is an emerging clinical treatment option for non-Hodgkin’s lymphoma (NHL) that combines the target specificity of monoclonal antibodies with the cytotoxicity of targeted r...
|
Peter S. Conti
|
2-3
|
|
|
|
Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)
Abstract: Patients with low-grade, follicular non-Hodgkin’s lymphoma usually present with advanced disease, which is not considered curable with conventional therapies. New approaches are needed to im...
|
Hossein Borghaei,
Russell J. Schilder
|
4-9
|
|
|
|
Imaging and dosing in radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)
Abstract: Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation chelator tiuxetan, which attaches the high-energy pure β emitte...
|
Stewart M. Spies
|
10-13
|
|
|
|
Logistics of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin)
Abstract: Radioimmunotherapy is a promising new therapeutic option for the treatment of B-cell non-Hodgkin’s lymphoma. Several monoclonal antibody and radionuclide conjugates, including I-131 tositumo...
|
A.Michael Zimmer
|
14-19
|
|
|
|
Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin)
Abstract: Radioimmunotherapy is a recently approved treatment modality for non-Hodgkin’s lymphoma that enables physicians to target cytotoxic localized radiation to tumor sites without using external-...
|
Xiaowei Zhu
|
20-23
|
|
|
|
Table of contents
To view a print version, click "View print version (PDF)" in the gray box above.
|
|
RF1
|
|
